PG004
Semaglutide biosimilar
Pipeline
Obesity and Diabetes
Semaglutide
Semaglutide
Biosimilar
A new game changer in the diabetes and obesity treatment market
Features
Next generation obesity and diabetes treatment based on GLP-1 analogue that lasts for one week
-
Maintaining blood sugar through regulation of insulin and glucagon secretion
-
Weight loss by suppressing appetite through nervous system
Originator
Mechanism
Semaglutide’s core mechanism of action
It’s an analog of GLP-1(glucagon-like peptide-1) and activated the gastrointestinal hormone ‘incretin’ to control blood sugar levels and reduce weight
Obesity
Semaglutide delays the rate at which food is expelled from the stomach and acts on the appetite center to suppress appetite and increase satiety, thereby reducing the amount of food consumed and resulting in weight loss
Diabetes
Semaglutide regulates blood sugar by stimulating pancreatic beta cells to increase insulin secretion and inhibiting glucagon secretion
Alzheimer's
Phase 3 clinical trials for Alzheimer's disease are currently underway
Equivalence analysis results
LC and MS analysis confirmed more than 99% similarity to the originator
As a result of cAMP analysis using a GLP-1 recptor expressing cell line, it was confirmed to be more than 99% similar to the originator
Semaglutide biosimilar research and development results
As a result of the development of a semaglutide biosimilar, PEPGENE has completed the development of a biosimilar that is more than 99% similar to the original semaglutide